STOCK TITAN

Kura Oncology (KURA) SEC Filings, Jun-Aug 2026

KURA NASDAQ

Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.

Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.

Rhea-AI Summary

Kura Oncology, Inc. is a commercial-stage biopharmaceutical company focused on precision oncology, now generating its first product revenue from KOMZIFTI (ziftomenib) for relapsed or refractory NPM1-mutated AML in the United States. For the six months ended June 30, 2026, total revenue was $39.1 million, including $14.9 million in KOMZIFTI net product revenue and $24.3 million in collaboration revenue from its global ziftomenib partnership with Kyowa Kirin.

Research and development expenses were $127.2 million, reflecting ongoing ziftomenib combination trials and darlifarnib Phase 1 work, while selling, general and administrative expenses rose to $63.3 million as commercial and corporate infrastructure expanded. Kura reported a net loss of $141.7 million, or $1.60 per share, compared with $123.6 million a year earlier, and used $148.4 million of cash in operating activities in the first half.

Liquidity remains significant, with $70.2 million in cash and cash equivalents and $448.8 million in short-term investments, totaling $519.0 million at June 30, 2026, plus a term loan facility. The company states it believes this balance, together with anticipated $180.0 million in additional Kyowa payments, will fund its current plan into late 2027 and through first topline KOMET-017 results anticipated in 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
quarterly report
-
Rhea-AI Summary

Kura Oncology reported second quarter 2026 results, highlighting early commercial traction for KOMZIFTI (ziftomenib) in relapsed or refractory NPM1-mutated AML. Net product revenue was $9.1 million, with approximately 115 new patient starts and more than 250 total prescriptions, all growing strongly versus the prior quarter, and KOMZIFTI achieved a majority share of new patient starts in its menin inhibitor class.

Total revenue was $20.9 million, including $11.8 million of collaboration revenue. Kura recorded a net loss of $68.3 million, with R&D expense of $61.9 million and SG&A of $31.8 million. Cash, cash equivalents and short-term investments were $519.0 million as of June 30, 2026, and together with $180 million in anticipated collaboration payments, management expects funding to support the ziftomenib AML program through topline Phase 3 KOMET-017 results anticipated in 2028.

Clinical updates showed high and durable responses for ziftomenib combinations in frontline and relapsed AML, and encouraging activity for darlifarnib combinations across KRAS-mutated tumors and clear cell renal cell carcinoma, supporting its positioning as a precision combination platform and multiple ongoing and planned studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
current report
-
Rhea-AI Summary

Kura Oncology amended and restated executive employment agreements for its Chairman, President and CEO Troy E. Wilson, Chief Commercial Officer Brian Powl and Chief Operating Officer Kathleen Ford to modify severance protections, including change‑of‑control terms tied to a Corporate Transaction.

If Wilson is terminated without Cause or resigns for Good Reason outside the Corporate Transaction window, he receives a lump sum equal to 12 months base salary, up to 12 months COBRA premiums and a 12‑month stock option exercise period. If the separation occurs within 59 days before, on, or within 18 months after a Corporate Transaction, his cash severance increases to 24 months salary plus 200% of target bonus, with up to 24 months COBRA, full equity vesting at target and a 12‑month option exercise period. Powl and Ford receive similar protections, with 12 months salary outside a Corporate Transaction and, within the transaction window, 18 months salary, 150% of target bonus, extended COBRA, full equity vesting and a 12‑month option exercise period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
current report
Rhea-AI Summary

Kura Oncology, Inc. Chief Medical Officer Mollie Leoni sold 84,929 shares of common stock in an open-market transaction on June 18, 2026 at a weighted average price of $9.8233 per share. The trades were executed in multiple lots at prices ranging from $9.56 to $9.98.

The shares sold had been acquired upon vesting of restricted stock units and performance restricted stock units between January 26, 2022 and January 26, 2026. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. Following this transaction, Leoni directly holds 182,345 Kura Oncology shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
insider
-
Rhea-AI Summary

Kura Oncology, Inc. officer Mollie Vanessa Leoni gave notice of a proposed sale of 84,929 common shares, with an aggregate market value of approximately $812,770.53. The approximate sale date is June 18, 2026. The shares were acquired as restricted stock units and, according to the remarks, were acquired upon vesting between January 26, 2022 and January 26, 2026.

The notice lists 88,774,365 shares outstanding and March 19, 2026 as the date of plan adoption or giving of instruction for reliance on Rule 10b5-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
other
-
Rhea-AI Summary

Kura Oncology, Inc. director Diane L. Parks received an option grant for 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. According to the grant terms, it vests in full on the one-year anniversary of the grant date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
insider
Rhea-AI Summary

Kura Oncology director Michael Vasconcelles received a new stock option grant covering 35,000 shares of common stock. The option has an exercise price of $8.77 per share and was granted at no upfront cost. It vests in full on the one-year anniversary of the grant date and expires on June 3, 2036. Following this award, Vasconcelles holds options for 35,000 shares directly, reflecting a compensation-related grant rather than an open-market trade.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
insider
-
Rhea-AI Summary

Kura Oncology, Inc. director Faheem Hasnain reported receiving an option grant to purchase 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. Following this grant, Hasnain holds options for 35,000 shares. The award vests in full on the one-year anniversary of the grant date, making it a standard equity compensation grant rather than an open-market purchase.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
insider
-
Rhea-AI Summary

Kura Oncology director Helen Louise Collins received a new stock option grant that increases her potential equity stake in the company. She was awarded options to purchase 35,000 shares of common stock at an exercise price of $8.77 per share. The options vest in full on the one-year anniversary of the grant date and expire on June 3, 2036. Following this grant, she holds options covering 35,000 shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
insider
Rhea-AI Summary

Kura Oncology director Carol Schafer received a grant of stock options, acquiring options to purchase 35,000 shares of common stock at an exercise price of $8.77 per share. These options vest in full on the one-year anniversary of the grant date and expire on June 3, 2036. Following this compensation-related award, Schafer holds 35,000 options directly, with no indication of open-market buying or selling in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
insider

FAQ

How many Kura Oncology (KURA) SEC filings are available on StockTitan?

StockTitan tracks 130 SEC filings for Kura Oncology (KURA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Kura Oncology (KURA)?

The most recent SEC filing for Kura Oncology (KURA) was filed on November 19, 2026.